New Cystic Fibrosis Triple From Vertex Backed for NHS Use

New cystic fibrosis triple from Vertex backed for NHS use

Vertex has won NICE's backing for a new cystic fibrosis therapy, Alyftrek, that could be an option for 89% of NHS patients with the genetic disorder.

NHS England Secures Access to New Cystic Fibrosis Treatment

NHS England has reached a reimbursement agreement with Vertex Pharmaceuticals for ALYFTREK, a once-daily triple therapy for cystic fibrosis (CF) eligible for patients aged six and over. This next-generation treatment, approved following a positive recommendation from NICE, targets those with at least one F508del mutation or another responsive mutation in the CFTR gene. As Vertex’s fifth CF medicine, ALYFTREK represents a significant milestone in…

NHS England secures access to new cystic fibrosis treatment ALYFTREK

Vertex’s once-daily triple therapy approved for eligible patients aged six and over

Vertex and NHS England sign reimbursement agreement

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek.

NHS to roll out groundbreaking triple therapy for cystic fibrosis patients

The NHS will provide a new triple combination therapy to hundreds of children and adults with cystic fibrosis in England, aiming to improve lung function and quality of life for eligible patients Hundreds of children and adults living with cystic fibrosis in England are set to benefit from a newly approved triple combination therapy, following an announcement by NHS England. The rollout marks a significant advancement in treatment, offering impr…

NHS England Makes Groundbreaking Cystic Fibrosis Drug ALYFTREK Available: Superior to Current Treatments

Next-generation CF treatment now available for patients 6+ in England. Shows improved outcomes vs KAFTRIO. Revolutionary once-daily therapy reaches more patients. Learn more.